You have no items in your shopping cart.
Description
Olpasiran is a first-in-class, high-purity small interfering RNA (siRNA) designed to target and inhibit Lipoprotein(a) [Lp(a)] mRNA translation in hepatocytes, thereby reducing plasma Lp(a) concentration. As a precision molecular tool, Olpasiran enables researchers to study the modulation of Lp(a) levels and its impact on cardiovascular risk factors in preclinical and in vitro studies.
Supplied as a solid powder with >99% purity by HPLC, Olpasiran is soluble in DMSO and can be stored at room temperature for several months or at -20°C for long-term storage up to 3 years. This siRNA is an essential reagent for molecular biology, RNA interference, and lipid metabolism research.
Specifications
| Product Name | Olpasiran |
| Chemical Formula | (Duplex): C490H652F11N164O306P41S7 |
| Molecular Weight | 15438.70 |
| CAS# | 2225856-03-9 |
| Appearance | Solid powder |
| Purity | > 99% by HPLC |
| Solubility | Soluble in DMSO |
| Storage | Room temperature for months, or -20ºC for 3 years |
Product information
Targets: Lipoprotein(a); Lipoprotein
Synonym: Olpasiran
Features
-
First-in-Class siRNA: Specifically designed to inhibit LPA mRNA translation in hepatocytes.
-
High Purity: >99% purity by HPLC ensures consistent and reliable experimental results.
-
Targeted Lipoprotein Modulation: Effectively reduces plasma Lipoprotein(a) levels for cardiovascular and lipid research studies.
-
Soluble and Stable: Soluble in DMSO; stable at room temperature for months or at -20°C for long-term storage.
-
Research-Grade Quality: Suitable for molecular biology, RNA interference, and lipid metabolism studies.
Applications
-
Cardiovascular Research: Investigate the role of Lp(a) in atherosclerosis, thrombosis, and lipid metabolism.
-
RNA Interference Studies: Examine gene silencing effects targeting LPA mRNA in hepatocytes.
-
Molecular Biology Research: Study Lp(a)-related pathways and cellular lipid regulation.
-
Drug Development Research: Evaluate potential therapeutics for hyperlipoproteinemia and cardiovascular disorders.
-
Preclinical Studies: Assess functional outcomes of Lp(a) reduction in vitro and ex vivo models.
References
https://gsrs.ncats.nih.gov/ginas/app/beta/substances/8M4GC1EOB4
https://drugs.ncats.io/substance/8M4GC1EOB4
https://pubchem.ncbi.nlm.nih.gov/substance/472420032
Document
Disclaimer: For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.

